Acadia Pharmaceuticals Inc (ACAD) Stock Price & Analysis
Acadia Pharmaceuticals Inc (ACAD) rose 0.65% to USD 21.84 as of June 10, 2026 at 00:59 UTC, according to Nexqual real-time market data.
ACAD last closed at USD 21.7; the session ranged USD 21.47–22.03 on volume of 1,104,652 shares. Market capitalization is $3.74B, with a 52-week range of USD 19.69–28.35 (NMS). Source: Nexqual, June 10, 2026 at 00:59 UTC.
Key Statistics (as of June 10, 2026 at 00:59 UTC)
| Price | USD 21.84 |
|---|---|
| Change | ▲ 0.65% (up) |
| Previous Close | USD 21.7 |
| Open | USD 21.86 |
| Day Range | USD 21.47 – 22.03 |
| 52-Week Range | USD 19.69 – 28.35 |
| Volume | 1,104,652 shares |
| Market Cap | $3.74B |
| Exchange | NMS |
Technical Analysis (ACAD)
Nexqual's technical model rates ACAD "NEUTRAL" based on 3 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 00:59 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.6 (neutral) |
| vs SMA50 | Above (USD 21.81) |
| MACD | -0.05 (negative) |
Analyst Ratings (ACAD)
Wall Street analysts rate ACAD "None" based on 20 analysts, with a mean price target of USD 31.65 (range USD 17–45), per Nexqual as of June 10, 2026 at 00:59 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 31.65 |
| High Target | USD 45 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 16 / 4 / 1 |
Earnings (ACAD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $295.29M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.02 vs est 0.08 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.14 ▼ miss |
| 2025-09-30 | USD 0.42 vs est 0.15 ▲ beat |
| 2025-06-30 | USD 0.16 vs est 0.14 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financials & Fundamentals (ACAD)
| Total Revenue | $1.10B |
|---|---|
| Revenue Growth (YoY) | +9.70% |
| Gross Margin | +61.58% |
| Operating Margin | -1.72% |
| Profit Margin | +34.30% |
| ROE | +37.32% |
| Debt / Equity | 4.07 |
| Current Ratio | 3.59 |
| Total Cash | $851.46M |
| Total Debt | $50.79M |
| Free Cash Flow | $154.14M |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Financial Health Score (ACAD)
Nexqual rates Acadia Pharmaceuticals Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:59 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 62%, operating -2% |
| Balance Sheet | Strong — $851M cash vs $51M debt, net cash position |
| Cash Flow | Solid — FCF $154M, 14% margin |
| Efficiency | Strong — ROE 37%, ROA 3.7% |
Ownership (ACAD)
| Insider Ownership | +0.32% |
|---|---|
| Institutional Ownership | +99.08% |
| Shares Outstanding | 171.24M |
| Float | 127.30M |
| Short % of Float | +10.89% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
Leadership (ACAD)
Acadia Pharmaceuticals Inc is led by Catherine E. Owen Adams (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 00:59 UTC.
| CEO & Director | Catherine E. Owen Adams (age 55) |
|---|---|
| Executive VP & CFO | Mark C. Schneyer (age 51) |
| Senior Vice President of Investor Relations & Corporate Communications | Albert S. Kildani |
| Senior Vice President of Finance | James K. Kihara (age 44) |
| Senior Vice President of Rare Disease Franchise | Allyson McMillan-Youngblood |
Major Backers & Investors (ACAD)
Notable institutional backers of Acadia Pharmaceuticals Inc include Baker Bros. Advisors, LP, RTW Investments LP, First Trust Advisors LP, according to Nexqual as of June 10, 2026 at 00:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 25.05% |
| RTW Investments LP | 4.17% |
| First Trust Advisors LP | 1.95% |
| Palo Alto Investors Lp | 1.68% |
| Fidelity | 0.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 19.51% |
| Vanguard Group | 14.23% |
| State Street | 7.77% |
| Geode Capital | 2.02% |
| Dimensional Fund Advisors | 1.84% |
Source: Nexqual, June 10, 2026 at 00:59 UTC.
From Acadia Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
- The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
- It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
- In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | USD 15.89 | ▲ 0.89% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
| CLDX | Celldex Therapeutics, Inc. | USD 29.6 | ▲ 3.42% |
| EXEL | Exelixis, Inc. | USD 52.99 | ▲ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:59 UTC. This page is informational and not investment advice.